Testimonials

Dick Davis Investment Digest quotes advice from Global-Investing.com

Dick Davis Investment Digest quotes advice from Global-Investing.com:

“Given Chinese steel growth, I looked at Ossen
Innovation Co. Ltd. (OSN 3.00 Nasdaq), a Nasdaq-
listed steel-wire maker which also makes rare-earth
coated steels. These are used for building suspension
bridges. While a likely beneficiary of the Chinese boom
in infrastructure spending, it also engaged in complex
self-dealing with its CEO, who owns a tad under 60%
of OSN stock. Of the remaining shares, most were in
institutional hands but they seem to be selling, so the
instituional share has fallen from 25% to about 5% in
2011 to date. A shortage of stock in a closely held firm
among other things leads to its reporting with delays,
and it only just put out its 2010 annual numbers. It also
increases volatility, as does the market’s current taste for
shorting recently issued Chinese shares (this one came
out in December 2010). The share fell Friday by about
10% despite the figures looking good but recovered a bit
this morning. OSM is hardly tracked by Wall Street as
only one firm covers it. It has a P/E ratio of 3.69 (TTM)
which is appealing. Its growth has been rapid and its
margins are around 20%. It trades at 1.1x book. It is a
gamble but I am taking it. … Buy OSN with restraint.”
 

Issue 700 of the Dick Davis Investment Digest
Newsletter rater Mark Hulbert rates Global Investing as a good way for investors to improve their returns and reduce their risk.
This newsletter focuses on investing in overseas markets, primarily in the equity arena though on occasion in the fixed-income arena as well. No explicit market timing advice is provided. Recommendations come in the form of buy/hold/sell advice on individual stocks and bonds as well as closed-end mutual funds.
Contact Information
35 Sutton Place
New York, NY 10022-2464

212-758-9480
publisher@global-investing.com
www.global-investing.com

Subscription Information
1-year subscription price: $369.00
Frequency of publication: Daily
Year publication commenced: 1989
Year HFD tracking commenced: 1994
Investment focus: gold, equities, intl. equities, fixed income
Investment instruments: stocks, bonds
Performance Summary (annualized)
Raw returns Newsletter Wilshire 5000
1-year 14.86% 20.73%
3-years 8.22% 3.51%
5-years 9.52% 3.01%
10-years 13.63% 3.67%
Sharpe Ratio Newsletter Wilshire 5000
1-year 0.35* 0.43*
3-years 0.12* 0.08*
5-years 0.13* 0.05*
10-years 0.19* 0.05*
* Performance divided by risk; a higher number is preferable

Newsletter Performance (cumulative)
Hulbert's Financial Digest, a Dow-Jones publication
A Sale Reported

Last recommended in Dividend Digest issue 208 dated January 13, 2010, at 41.56 by Global Investing:
“We do not often trade high-yielding portfolio shares, but information from a potential competitor to GlaxoSmithKline plc (GSK 38.99 NYSE – yield 5.20%) is worrying our biotech maven, who writes about developments that will hurt GSK: ‘It won’t have an immediate affect but Amarin is developing a compelling competitor to the 1 billion market for GSK’s Lovaza (to treat high triglycerides). The new drug, AMR101, has a better effectiveness profile, better safety, and requires less frequent dosing.’ ... Vivian adds: Also worrying about GSK is poor results from a European competitor, Roche, today and a drying out pipeline of new patents. Making enough money to cover the high dividend requires that GSK keep up its prices, under siege in Europe by price-controllers, and in the USA by healthcare reformers. Today, I expect GSK’s share price will rise a bit because of the sale of its stake in Quest Diagnostics (DGX), which will produce some cash. But I do not think there will be enough in the kitty for a game-changing acquisition. Meanwhile its key vaccination business, which distinguishes GSK from pharma rivals, is under renewed fire. The United Nations World Health Organization has called for further investigation into a possible link between a common flu vaccine and narcolepsy, a find by a Finnish study reported yesterday. ... Replace GSK.”
Vivian Lewis, Global Investing, www.global-investing.com, 212-758-9480, 2/2/11

from Dick Davis Income Digest, Jan. 2011
Mark Hulbert Reports on Global Investing's Track Record

Global Investing

 

$ Purchase Full Hulbert's Financial Digest Newsletter Profile

 
 

This newsletter focuses on investing in overseas markets, primarily in the equity arena though on occasion in the fixed-income arena as well. No explicit market timing advice is provided. Recommendations come in the form of buy/hold/sell advice on individual stocks and bonds as well as closed-end mutual funds.

 

 


 


212-758-9480
publisher@global-investing.com
www.global-investing.com

 

Subscription Information

 

1-year subscription price: $369.00

Frequency of publication: Daily

Year publication commenced: 1989

Year HFD tracking commenced: 1994

Investment focus: gold, equities, intl. equities, fixed income, gold, equities, intl. equities, fixed income

Investment instruments: stocks, bonds, Closed-end and Exchange-Traded Funds

 

Performance Summary (annualized)

 

Raw returns

Newsletter

1-year

15.42%

3-years

4.46%

5-years

10.78%

10-years

12.27%

Risk adjusted returns

Newsletter

1-year

98.32%

3-years

122.69%

5-years

123.77%

10-years

120.91%

 

Newsletter Performance (cumulative)


 

Newsletter Specific - Global Investing

From Hulbert's Financial Digest
Global Investing has beaten the market over the last five-, 10- and 15-year periods, according to Hulbert

Dick Davis DigestI wanted to warn you all not to take too seriously the latest ominous chart pattern, named after the Blimp Hindenburg. Yes, it blew up and set back the cause of motorless flight for decades. But a Hindenburg is clearly not as disastrous as a Death Cross, the last chartist panic call two months ago, which was followed by a normal flat market since then. Neither chart pattern has a long-term convincing history. They are just used by bears to scare us off the stock market.

Dick Davis Digest - September 2010 - Volume 29, Issue 678